India is increasingly a dominant destination for global pharmaceutical companies looking to outsource early-stage drug discovery.
The spillover effect of this contagion has also spread to local players. Prompted by the introduction of new patent laws in 2005, Indian companies such as Nicholas Piramal, Cipla, Dr Reddy's Laboratories and Ranbaxy have risen to the forefront of the life sciences world with discovery programs of their own.